Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7212773 | 0.97 | BLM (0.40) | TSHRGABRR1SLC6A1SLC6A13GABRP | |
| SCHEMBL9806461 | 0.89 | TSHR (0.34) | TSHRGABRR1SLC6A1SLC6A13GABRP | |
| SCHEMBL10765966 | 0.79 | — | — | |
| SCHEMBL10699564 | 0.75 | CYP3A4 (0.44) | TSHRLMNAMAPK1HSD17B10TDP1 | |
| SCHEMBL30679250 | 0.74 | — | — | |
| SCHEMBL13140760 | 0.73 | TSHR (0.39) | TSHRGABRR1SLC6A1SLC6A13GABRP | |
| SCHEMBL3652674 | 0.70 | — | — | |
| SCHEMBL7373583 | 0.69 | — | — | |
| SCHEMBL11477504 | 0.69 | TSHR (0.46) | TSHRGABRR1SLC6A1SLC6A13GABRP | |
| SCHEMBL11379945 | 0.67 | TSHR (0.31) | TSHRGABRR1SLC6A1SLC6A13GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801510-B1 | COMPOUNDS INCREASING THE EXPRESSION OF SARCOSPAN FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHY | UNIV CALIFORNIA (US) | 2025-04-23 | — | — | EP | claimed |
| EP-3707143-B9 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2023-04-12 | — | — | EP | claimed |
| EP-3707143-B1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2022-12-28 | — | — | EP | claimed |
| CN-113121418-A | Preparation method of 1, 4-dihydropyridine-3, 5-dimethylamide compound | 上海应用技术大学 | 2021-07-16 | — | — | CN | claimed |
| EP-0716081-B1 | Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives | BAYER HEALTHCARE AG (DE) | 2006-04-05 | — | — | EP | claimed |
| US-20040248099-A1 | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | claimed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | claimed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | claimed |
| US-6545028-B2 | Antiepileptic agents, hypotensive agents; monitoring membrane potentials | NEUROSEARCH A/S (DK) | 2003-04-08 | — | — | US | claimed |
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | claimed |
| EP-0194906-B1 | HETEROCYCLIC DISSYMMETRIC 1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | FOURNIER INNOVATION ET SYNERGIE (FR) | 1989-07-19 | — | — | EP | claimed |
| US-4806544-A | ENANTIOMORPHS, RACEMIC MIXTURES, HYPOTENSIVE AGENTS, CARDIOV LAR DISORDERS | FOURNIER INNOVATION ET SYNERGIE (FR) | 1989-02-21 | — | — | US | claimed |
| US-4737506-A | Anti-arteriosclerotic pyridyl or imidazolyl derivatives of carbonyloxyalkyl hantzsch esters | KOWA CO., LTD. (JP) | 1988-04-12 | — | — | US | claimed |
| US-4730052-A | Method for preparing unsymmetrical 1,4-dihydropyridine-3,5-dicarboxylic acid diesters | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1988-03-08 | — | — | US | claimed |
| US-4710505-A | VASODILATORS, HYPOTENSIVES | SOCIETE DE RECHERCHES INDUSTRIELLES (S.O.R.I.) (FR) | 1987-12-01 | — | — | US | claimed |
| EP-0225175-A2 | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof | FISONS plc (GB) | 1987-06-10 | — | — | EP | claimed |
| EP-0223744-A2 | Flavone derivatives | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1987-05-27 | — | — | EP | claimed |
| EP-0190364-A1 | NOVEL 1,4-DIHIDROPYRIDINE-3,5-DICARBOXYLATE DERIVATIVES | KOWA CO. LTD. (JP) | 1986-08-13 | — | — | EP | claimed |
| EP-0168789-A2 | Method for preparing unsymmetrical 1,4-dihydropyridine-3,5-dicarboxylic acid diesters | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1986-01-22 | — | — | EP | claimed |
| EP-0097821-A2 | Dihydropyridines with an antagonistic activity to calcium, process for their preparation, and pharmaceutical compositions containing them | Pierrel S.p.A. (IT) | 1984-01-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | KCNN2, KCNN1, KCNJ2 | TSHR 3860/4885GABRR1 272/4885SLC6A1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.